Accolade, Inc. is a company in the U.S. stock market and it is a holding in 46 U.S.-traded ETFs. ACCD has around 10.8M shares in the U.S. ETF market. The largest ETF holder of ACCD is the ARK Genomic Revolution ETF (ARKG), with approximately 5.74M shares. Investors may also find of interest that the ETF with the largest allocation to ACCD stock is ARK Genomic Revolution ETF (ARKG), with a portfolio weight of 3.64%. On average, U.S. ETFs allocate 0.15% of ACCD to their portfolios.
Additionally, ACCD is a favorite stock for Vanilla and Active ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with ACCD as a holding is the Dimensional U.S. Targeted Value ETF (DFAT), with a return of 1.68%.